Ipsen’s partner Inspiration Biopharmaceuticals announces the initiation of the second phase III pivotal clinical study of OBI-1 in congenital hemophilia A with inhibitors

This article or press release has no online content. Please download the associated documents for more information.

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2023